Evidence map›Paper›PMID 42229803›Full record

ArticleThe Journal of biological chemistry2026

SARS-CoV-2 Nsp13 helicase resolves G-quadruplexes and is inhibited by G4 ligands or an antiviral regulator: Implications for G4 anti-coronavirus therapies.

Joe C George, Tomasz Kulikowicz, Pierce T Bombard, Martina Rossi, Adaira J Dumm, Olivia M Anderson, Joshua A Sommers, Robert M Brosh

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Joe C GeorgeHelicases and Genomic Integrity Section, Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, NIH Biomedical Research Center, Baltimore, Maryland, USA.
Tomasz KulikowiczHelicases and Genomic Integrity Section, Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, NIH Biomedical Research Center, Baltimore, Maryland, USA.
Pierce T BombardHelicases and Genomic Integrity Section, Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, NIH Biomedical Research Center, Baltimore, Maryland, USA.
Martina RossiHelicases and Genomic Integrity Section, Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, NIH Biomedical Research Center, Baltimore, Maryland, USA.
Adaira J DummHelicases and Genomic Integrity Section, Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, NIH Biomedical Research Center, Baltimore, Maryland, USA.
Olivia M AndersonHelicases and Genomic Integrity Section, Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, NIH Biomedical Research Center, Baltimore, Maryland, USA.
Joshua A SommersHelicases and Genomic Integrity Section, Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, NIH Biomedical Research Center, Baltimore, Maryland, USA.
Robert M BroshHelicases and Genomic Integrity Section, Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, NIH Biomedical Research Center, Baltimore, Maryland, USA. Electronic address: broshr@mail.nih.gov.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The COVID-19 pandemic is often viewed as a once-in-a-century event. However, the rise of new variants and the potential for infections from related coronaviruses continues to be a significant concern. Vaccines were a successful deterrent to COVID-19, but anti-coronavirus drugs to treat individuals with COVID-19 or Long COVID are not robust. Efforts to identify novel coronaviruses and host targets for drug therapies are highly valued. We determined that the SARS-CoV-2 Nsp13 helicase resolves G-quadruplexes (G4) of various topologies in an ATP-stimulated manner. Additionally, the requirement for a 5'-single-stranded tail flanking DNA-G4 indicates its 5'- to 3'-translocation directionality. G4 ligands were tested for inhibition of Nsp13 G4 resolvase. PhenDC3 inhibited Nsp13 resolution of four-stranded parallel G4 (IC

Indexed as

Antiviral AgentsDNA HelicasesG-QuadruplexesSARS-CoV-2Viral Nonstructural ProteinsCOVID-19COVID-19 Drug TreatmentHumansLigandsMethyltransferasesRNA HelicasesAntiviral AgentsDNA HelicasesLigandsMethyltransferasesNsp13 protein, SARS-CoVRNA HelicasesViral Nonstructural ProteinsCNBPcoronavirusCOVID-19G4G-quadruplexhelicaseSARS-CoV-2

Identifiers

PMID42229803
PMCPMC13325320

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.